

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61L 15/58, 24/06		A1	(11) International Publication Number: WO 00/45864
			(43) International Publication Date: 10 August 2000 (10.08.00)
(21) International Application Number: PCT/GB00/00304 (22) International Filing Date: 2 February 2000 (02.02.00) (30) Priority Data: 9902238.6 2 February 1999 (02.02.99) GB (71) Applicant (for all designated States except US): FIRST WATER LIMITED [GB/GB]; Hilddrop Lane, Ramsbury, Marlborough, Wiltshire SN8 2RB (GB). (72) Inventor; and (75) Inventor/Applicant (for US only): MUNRO, Hugh, Semple [GB/GB]; Barton Cottage, Weston Sub Edge, Chipping Camden, Warwickshire GL55 6QT (GB). (74) Agent: BROWN, David, Leslie; Page Hargrave, Southgate, Whitefriars, Lewins Mead, Bristol BS1 2NT (GB).		(81) Designated States: AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), DM, EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report.	

(54) Title: BIOADHESIVE COMPOSITIONS

(57) Abstract

A bioadhesive composition for use as a skin adhesive, the composition formed by polymerising with cross-linking and/or entanglement an aqueous reaction mixture comprising effective amounts of at least one monomer dissolved or suspended therein and capable of forming a hydrogel on polymerisation, optionally at least one cross-linking agent for the monomer, and water, said composition having an elastic modulus (G') and a viscous modulus (G''), wherein the degree of polymerisation and/or the degree of cross-linking and/or entanglement are selected to control the skin adhesion properties of the bioadhesive composition having regard to the rate of change of tan delta ($G'' \div G'$) against frequency in a diagnostic portion of the frequency range 0.01 to 300 rad/s, typically the lower end of the said frequency range below about 100 rad/s.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

BIOADHESIVE COMPOSITIONS

Field of the Invention

5 The present invention relates to bioadhesive compositions. One possible application of the compositions of the invention is as skin adhesives in the field of biomedical skin electrodes. These electrodes incorporate bioadhesive compositions which are electrically conductive. Another possible application of the compositions of the invention is as skin adhesives particularly in the field of medical skin coverings, particularly wound dressings.

10

Background of the Invention

Biomedical skin electrodes are widely used in a variety of situations, whenever for example it is required to establish an electrical connection between the surface of the body of a patient and external medical equipment for transmission of electrical signals.

15

Modern medicine uses many medical procedures where electrical signals or current are received from or delivered to a patient's body. The interface between medical equipment used in these procedures and the skin of the patient is usually some sort of biomedical electrode. Such electrodes typically include a conductor which must be connected electrically to the equipment, and a conductive medium adhered to or otherwise contacting the skin of the patient, and they are of varying types with a wide variety of design configurations which will generally depend on their intended use and whether for example they are to be used as transmission electrodes or sensing i.e. monitoring electrodes.

25

Among the therapeutic procedures using biomedical electrodes are transcutaneous electric nerve stimulation (TENS) devices used for pain management; neuromuscular stimulation (NMS) used for treating conditions such as scoliosis; defibrillation electrodes to dispense electrical energy to a chest cavity of a mammalian patient to defibrillate heart beats of the patient; and dispersive electrodes to receive electrical energy dispensed into an incision made during electrosurgery.

30

-2-

Among diagnostic procedures using biomedical electrodes are monitors of electrical output from body functions, such as electrocardiograms (ECG) for monitoring heart activity and for diagnosing heart abnormalities.

For each diagnostic, therapeutic, or electrosurgical procedure, at least one biomedical electrode having an ionically conductive medium containing an electrolyte is adhered to or is otherwise contacted with mammalian skin at a location of interest and is also electrically connected to electrical diagnostic, therapeutic, or electrosurgical equipment. A critical component of the biomedical electrode is the conductive medium which serves as the interface between the mammalian skin and the diagnostic, therapeutic, or electrosurgical equipment, and which is usually an ionically conductive medium.

Biomedical electrodes are used among other purposes to monitor and diagnose a patient's cardiovascular activity. Diagnostic electrodes are used to monitor the patient immediately and are only applied to the patient for about five to ten minutes. Monitoring electrodes, however, are used on patients in intensive care for up to three days continuously. In contrast, Holter electrodes are used to monitor a patient during strenuous and daily activities.

Although all of the biomedical electrodes just referred to are used to record cardiovascular activity, each electrode requires specific features or characteristics to be successful. Thus, the diagnostic electrode does not have to remain adhered to a patient for extensive periods but it does have to adhere to hairy, oily, dry and wet skin effectively for the five to ten minutes of use. The monitoring electrode has to adhere for a longer period of time although the patient is often immobile during the monitoring period. The Holter electrode is susceptible to disruption from adhesion due to physical motion, perspiration, water, etc., and therefore requires the best adhesion and at the same time comfort and electrical performance.

In the biomedical electrodes known in the prior art the ionically conductive medium which serves as an interface, between the skin of a mammalian patient and the electrical instrumentation, ranges from conductive gels and creams to conductive pressure

sensitive adhesives. However, while the conductive media can be in the form of pressure sensitive conductive adhesives, for monitoring or Holter biomedical electrodes the use of such conductive adhesives is not generally adequate on their own to maintain adhesion to mammalian skin and additional hypoallergenic and hydrophobic pressure sensitive adhesives may be employed around the conductive medium to provide the required mammalian skin adhesion. U.S. Patent No. 5012810 (Strand et al.) and U.S. Patent Nos. 4527087, 4539996, 4554924 and 4848353 (all Engel), the disclosures of which are incorporated herein by reference, are examples of documents that disclose biomedical electrodes which have a hydrophobic pressure sensitive adhesive surrounding the conductive medium.

10

In general, a desirable skin electrode is one which maintains good electrical contact with the skin and is free of localised current hot spots, i.e. exhibits uniform conductivity. For example, it has been found that a prior art electrode utilising karaya-gum tends to creep in use and flatten out, exposing skin to possible direct contact with the current distribution member or lead wire. A desirable skin electrode should also usually have a low electrical impedance.

15

As mentioned above, another possible application of the compositions of the invention is in the field of medical skin coverings, for example medical tapes, wound dressings and bandages, and most particularly wound dressings. In general, a desirable wound dressing bioadhesive composition maintains good adhesion to skin of varying moisture levels, while maintaining the dressing in position on the skin and permitting moisture and skin exudates to be transmitted away from the skin. The bioadhesive composition may suitably incorporate an antimicrobial agent, to reduce the possibility of infection of the wound. US Patent No. 5670557 (Dietz et al) and the prior art referred to therein, the disclosures of which are incorporated herein by reference, are examples of documents that disclose wound dressings which have a pressure sensitive adhesive which maintains the wound dressing in position on the skin.

20

25

30 EP-A-0850625 and EP-A-0850649 (The Procter & Gamble Company), the disclosures of which are incorporated herein by reference, describe a topical adhesive for application

of functional articles to the skin, the functional articles being cosmetic or pharmaceutical delivery articles, decorative or cleaning articles (EP-A-0850649) or disposable absorbent articles (EP-A-0850625). The adhesive has particular selected rheological properties, which are expressed in part by using the difference between the elastic modulus and the viscous modulus at two fixed frequencies of applied stress, namely 1
5 rad/sec and 100 rad/sec.

Summary of the Invention

It is an object of this invention to provide hydrogel skin adhesives possessing controlled and predictable adhesive properties which may be readily varied to suit different uses
10 and, in the case of medical electrodes, wound dressings or similar devices, different configurations or applications.

Adhesives used for skin contact applications need to exhibit both good levels of adhesion and pain free removal. The adhesive must be skin compatible and not be harsh
15 or aggressive towards the skin or cause skin irritation or inflammation.

The problem of achieving the desired level of adhesion is exacerbated under wet conditions. Conventional bioadhesives generally provide poor adhesion to wet skin, such adhesion generally reducing as water is absorbed by the bioadhesive. It is hence
20 very important that the adhesive is also stable to exposure to excess quantities of liquid, such as water and in some applications in particular to urine or blood, so that it will not lose its adhesive strength on exposure to water.

Individual aspects of the invention aim, respectively, to provide hydrogel skin adhesives
25 which provide good adhesion to moist and wet skin and such adhesives for use in biomedical skin electrodes or wound dressings. These hydrogels would be useful for adhesion to skin which is subject to flushing by water or aqueous solutions. In such circumstances there is a need for materials capable of adhering to skin that can maintain or increase their adhesion on water up-take.

30

Thus the present invention seeks in one aspect to provide a bioadhesive which adheres to wet skin, is stable and maintains its adhesiveness even when exposed to excessive amounts of liquid.

Other aspects of the present invention aim to control and adjust the extent to which the
5 bioadhesive maintains or loses its adhesiveness on exposure to liquid.

Examinations of the rheological properties of adhesives have been successfully used to characterise and differentiate adhesive behaviour. See, for example, "Viscoelastic Properties of Pressure Sensitive Adhesives" in The Handbook of Pressure Sensitive
10 Adhesives (ed. D. Satas) pages 158 to 203 (1989). Typically, the elastic modulus (G') and the viscous modulus (G'') are measured in a controlled stress rheometer, e.g. a parallel plate rheometer using a film sample of the bioadhesive composition between the plates, over a frequency range of 0.01 - 300 rad/s at a given temperature. For skin applications the appropriate temperature is 37°C. The moduli at low frequencies relate
15 to the initial bonding of the adhesive to skin and the moduli at higher frequencies to de-bonding. For conventional prior art hydrogel adhesives both G' and G'' increase within increasing frequency. On absorption of water these trends are maintained but the absolute values of the moduli decrease. The ratio of G'' to G' ($G'' \div G'$) is referred to as tan delta. This gives an indication of the balance of contribution arising from the
20 viscous and elastic properties of the material. It is found that many conventional hydrogel based adhesives, on taking up water in an amount that exceeds 3% by weight of the as made bioadhesive, lose their adhesive properties. For such compositions tan delta tends to increase with increasing frequency. In some cases the curve of tan delta plotted against frequency may show a point of inflexion or a maximum at relatively high
25 frequencies, i.e. the rate of change of the tan delta curve may be zero at one or more point. However the general trend is that tan delta increases at low frequencies with increasing frequency. High values of tan delta at high frequency indicate an increasing contribution to the de-bonding process associated with the viscous component of the gel.

30 We have found that the behaviour of tan delta, when plotted against frequency over a portion (typically the very low frequency end) of the normal frequency range 0.01 - 300

rad/s at 37°C is diagnostic of many of the skin adhesion properties found in the bioadhesive composition.

Moreover, we have found that the behaviour of tan delta, when plotted against frequency at these diagnostic frequencies, can be manipulated by adjustment of the amounts of certain components of the aqueous reaction mixture and by control of the polymerisation conditions, with the result that, for the first time, the skin adhesion properties of bioadhesive compositions can be controlled to a relatively high degree of accuracy, compared with the accuracy available hitherto.

10 According to a first aspect of the present invention, there is provided a bioadhesive composition for use as a skin adhesive, the composition formed by polymerising with cross-linking and/or entanglement an aqueous reaction mixture comprising at least one monomer dissolved or suspended therein and capable of forming a hydrogel on polymerisation, optionally at least one cross-linking agent for the monomer, and water,
15 said composition having an elastic modulus (G') and a viscous modulus (G''), wherein the degree of polymerisation and/or the degree of cross-linking and/or entanglement, are selected to control the skin adhesion properties of the bioadhesive composition having regard to the rate of change of tan delta ($G'' \div G'$) against frequency in a diagnostic portion of the frequency range 0.01 to 300 rad/s.

20 The selection of the degree of polymerisation and/or the degree of cross-linking and/or entanglement in the polymerised composition is suitably achieved by selection of the amount of monomer in the aqueous reaction mixture, the amount of any cross-linking agent present in the aqueous reaction mixture, and/or the reaction conditions for the
25 polymerisation with cross-linking and/or entanglement. This selection is within the abilities of one skilled in this art, the control parameters being discussed in more detail below.

The monomer may, for example, be at least one hydrophilic monomer, or a mixture of
30 at least one hydrophilic monomer with at least one hydrophobic monomer.

-7-

The bioadhesive composition may be used as a skin adhesive in a biomedical skin electrode or in a wound dressing. These uses of the bioadhesive composition are novel and constitute a second aspect of the present invention.

According to a third aspect of the present invention, there is provided a method for
5 preparing a bioadhesive composition for use as a skin adhesive, the method comprising:

- (a) forming an aqueous reaction mixture comprising at least one monomer dissolved or suspended therein and capable of forming a hydrogel on polymerisation, optionally at least one cross-linking agent for the monomer,
10 and water; and
 - (b) polymerising with cross-linking and/or entanglement the aqueous reaction mixture,
- 15 wherein the degree of polymerisation and/or the degree of cross-linking and/or entanglement, are selected to control the skin adhesion properties of the bioadhesive composition having regard to the rate of change of $\tan \delta$ ($G'' \div G'$) against frequency in a diagnostic portion of the frequency range 0.01 to 300 rad/s, where G'' is the viscous modulus of the bioadhesive composition and G' is the elastic modulus of the
20 bioadhesive composition.

According to a fourth aspect of the present invention, there is provided a method for controlling the skin adhesion properties of a bioadhesive composition for use as a skin adhesive, the method comprising polymerising with cross-linking and/or entanglement
25 an aqueous reaction mixture comprising at least one monomer dissolved or suspended therein and capable of forming a hydrogel on polymerisation, optionally at least one cross-linking agent for the monomer, and water; wherein the reaction is conducted so that the degree of polymerisation and/or the degree of cross-linking and/or entanglement is selected to control the skin adhesion properties of the bioadhesive composition having
30 regard to the rate of change of $\tan \delta$ ($G'' \div G'$) against frequency in a diagnostic

portion of the frequency range 0.01 to 300 rad/s, where G'' is the viscous modulus of the bioadhesive composition and G' is the elastic modulus of the bioadhesive composition.

- The measurement of elastic modulus and viscous modulus is carried out using a controlled stress rheometer at an appropriate temperature for the intended use of the bioadhesive (e.g. about 37°C). The controlled stress rheometer may suitably be a parallel plate rheometer, suitably testing a film of the bioadhesive composition between the parallel plates. Normally, the diagnostic effect of the rate of change of tan delta is best observed on the "as made" hydrogel before substantial uptake of water.
- 10 The expression "dissolved" as used herein includes all forms of dissolution and intimate monophasic admixture. The expression "suspended" as used herein includes all forms of intimate non-monophasic admixture, for example emulsification, including microemulsification.
- 15 The expression "diagnostic portion of the frequency range 0.01 to 300 rad/s" as used herein refers to that portion of the frequency range in which the rate of change of tan delta against frequency can be substantially reproducibly altered by control of the parameters stated herein and in which the said rate of change of tan delta correlates with skin adhesion properties of the bioadhesive composition.
- 20 It has been found, in particular, that bioadhesive compositions having useful adhesive responses to water uptake may exhibit a zero rate of change of tan delta against frequency at only one point in the frequency range 0.01 to 300 rad/s. Typically, the diagnostic portion of the frequency range 0.01 to 300 rad/s will be the portion below the frequency at which the zero point is observed.
- 25 This one point in the frequency range 0.01 to 300 rad/s may, for example, be a maximum or a minimum. When it is a maximum, a so-called "water unstable" bioadhesive composition is typically present. For further details of such compositions, reference is made to our International (PCT) Patent Application No. PCT/GB99/02524, the disclosure of which is incorporated herein by reference. When the point is a
- 30

minimum, a so-called "water stable" bioadhesive composition is typically present. For further details of such compositions, reference is made to our International (PCT) Patent Application No. PCT/GB99/02505, the disclosure of which is incorporated herein by reference.

- 5 For the purposes of the present invention "water-stability" will be defined as the maintenance of adhesion to skin or another substrate from a level of about 80% to more than 100% of the initial value of the hydrogel adhesive, after the water content of the hydrogel has increased by absorption of water from the environment external to the hydrogel. The amount of water absorbed may typically be from about 3% to about 30%
10 of the weight of the "as made" hydrogel. Correspondingly, "water-instability" will be defined as the reduction of adhesion to skin or another substrate to below about 80% of the initial value of the hydrogel adhesive, after the water content of the hydrogel has increased by absorption of water from the environment external to the hydrogel.

15 **Detailed Description of the Invention**

The skin adhesion properties to be controlled include initial adhesive strength, long-term adhesive strength, peel strength, wet skin performance, greasy skin performance, hair adhesion, residual adhesive amount after removal and cohesive strength.

- 20 The rate of change of tan delta against frequency, within the frequency range 0.01 to 300 rad/s or a diagnostic portion thereof, can be varied according to the invention within a range of negative values, between positive and zero, between negative and zero, or around zero. The zero value may be a continuous zero or a point zero. These variations will typically directly affect the adhesive properties of the composition, most
25 particularly the extent of maintenance or loss of adhesiveness in the presence of varying amounts of water or other liquids.

- The diagnostic portion of the frequency range 0.01 to 300 rad/s is typically the low-frequency end of the range, suitably below about 100 rad/s, more suitably below about
30 30 rad/s and most suitably below about 10 rad/s. At this low frequency end of the range, a positive rate of change of tan delta with increasing frequency (i.e. an increasing tan

-10-

delta with increasing frequency) is found in many cases to be diagnostic of water instability, and a negative or approximately zero rate of change of tan delta with increasing frequency (i.e. a decreasing tan delta within increasing frequency) is found in many cases to be diagnostic of water-stability.

- 5 It should be noted that the rate of change of tan delta is not necessarily constant over the diagnostic portion of the frequency range, and some variation is normal. Moreover, the diagnostic portion for one bioadhesive composition will not necessarily be the same as the diagnostic portion for another bioadhesive composition. For this reason, it may be necessary to conduct trials, in order to determine the diagnostic portion of the frequency
- 10 range for a particular bioadhesive composition. Such trials will be well within the ability of one of ordinary skill in this art.

Particular aspects of the polymerisation with cross-linking and/or entanglement which are susceptible to control according to the invention include:

15

1. the nature of the monomer(s) (M), in particular it/their reactivity and the number of polymerisable functions per molecule;
2. the nature of any cross-linking agent(s) (XL), in particular it/their reactivity
- 20 and the number of reactive functions per molecule;
3. the amounts of the monomer(s) in the aqueous reaction mixture;
4. the amount of any cross-linking agent(s) in the aqueous reaction mixture;
- 25 5. the presence of any polymerisation inhibitor(s);
6. the presence of any chain transfer agent(s);
- 30 7. the weight fraction of monomer(s) and cross-linking agent(s) in the reaction mixture;

-11-

8. in the case of an initiated polymerisation (e.g. free radical initiated polymerisation), the initiation efficiency (e.g. in the case of photoinitiation, the incident light intensity, the type of initiator and the incident wavelength distribution);
- 5 9. the reaction time;
10. any combination of 1 to 9.

Where a cross-linking agent (XL) is present, the relative amounts of M and XL (i.e. the
10 M:XL ratio) in the aqueous reaction mixture may have a significant effect on the adhesive properties of the bioadhesive composition, and this combination of aspects 3 and 4 above will typically require particular attention.

While the exercise of the control parameters according to the present invention may
15 require a small degree of practice and experiment on the part of the person skilled in the art, this is not an onerous task for such a person. All the control parameters - which are quantitatively monitorable by using the diagnostic tan delta measurements - are potentially reproducible and sufficiently defined to enable a substantially higher degree of control to be exerted on the preparation of bioadhesive hydrogels than has been
20 possible hitherto.

The M:XL molar ratio may suitably be selected within the range of about 10,000:1 to about 200:1. The M:XL molar ratio must necessarily be approximate, because the molecular weight of a number of commercially available cross-linking agents is not well
25 defined.

In any event, the appropriate M:XL ratio may readily be selected after simple experimentation to determine the controlling ratio, given the particular M and XL used and the desired adhesive properties of the composition, by monitoring the rate of change
30 of tan delta in the diagnostic portion of the frequency range 0.01 to 300 rad/s, in accordance with the present invention.

- According to one particular form of the invention, as described above, the rate of change of tan delta against frequency may equal zero at only one point in the frequency range 0.01 to 300 rad/s, more particularly in the frequency range 0.01 to 100 rad/s. A plot of the tan delta values against frequency over the specified range for the freshly produced
- 5 (as made) bioadhesive compositions of the invention may thus show a single (zero gradient) minimum value. The position of the minimum is dependent on the monomer composition, the degree of polymerisation, the degree of cross linking and/or entanglement, and/or the extent of plasticisation. Adhesive hydrogels exhibiting such rheological behaviour exhibit an increase in adhesion on water up-take whilst
- 10 maintaining pain free removal properties (i.e. "water stability" as defined herein). Without wishing to be bound by theory, the presence of a single (zero gradient) minimum in the tan delta plots may be interpreted as a truncation of the usual relaxation modes in the gel by a mechanism with a finite relaxation time. The minimum may be related to a sol component of the system (sol-non-crosslinked polymer component) such
- 15 that the viscous relaxation of the sol interrupts the relaxation of the network (cross-linked and/or entangled polymer). In these particular forms of the present invention, the sol characteristic, when coupled to sufficiently large values of G' and G'' , provides for materials with good adhesive strength capable of exhibiting increased adhesion on water absorption.
- 20
- Such water stable compositions exhibit surprisingly good adhesion to both dry and moist skin and on subsequent exposure to large amounts of water. In particular, the hydrogels in accordance with the invention generally provide adhesion on dry skin at no less than 0.5 N/cm. The compositions seem to provide good two stage adhesion with
- 25 a good initial "first stage" adhesion on first contact of the hydrogel with the skin which adhesion increases with time in the "second stage". Whilst providing sufficient adhesion, it is noted that the water stable hydrogel adhesives of the invention allow for pain free removal from the skin.
- 30
- Water stability is not always desirable. In some cases a certain loss of adhesion on water uptake may be desirable.

According to the present invention, water instability can be obtained by appropriate control of the extent of cross-linking and/or entanglement. For example, at higher cross-linking and/or entanglement levels than required for the water stable compositions, the rate of change of tan delta within the diagnostic portion of the frequency range 0.01 to 300 rad/s can become positive, a condition associated with water instability (substantial
5 loss of adhesion on water uptake). Our co-pending International (PCT) Patent Application No. PCT/GB99/02524 describes in more detail certain hydrogels which exhibit water instability at appropriate levels of cross-linking.

The findings that bioadhesive polymers have a diagnostic portion of the frequency range
10 0.01 to 300 rad/s, particularly less than about 100 rad/s, more particularly less than about 30 rad/s, and most particularly less than about 10 rad/s, in which the rate of change of tan delta against frequency correlates with bioadhesive properties, and moreover that this rate of change of tan delta can be affected, and even changed in its direction, by control of certain parameters of the aqueous reaction mixture and of the
15 polymerisation with cross-linking and/or entanglement, is surprising and unexpected.

Without wishing to be bound by theory, it is believed that the maximum degree of cross-linking and/or entanglement which is compatible with useful skin adhesion properties is reached when a maximum is observed in the loss compliance J'' , where

20

$$J'' = G'' / [(G')^2 + (G'')^2].$$

When such a maximum is observed in J'' , it will typically be at a radian frequency of less than about 30 rad/s, most suitably less than about 10 rad/s. This frequency range
25 for the observed J'' maximum is believed to determine the diagnostic frequency range for the particular composition under consideration. In this diagnostic portion of the frequency range the gel generally has a relaxation time of sufficient length that the gel does not flow under its own weight, the same property that is a necessary characteristic of certain important applications of bioadhesive compositions, particularly in biomedical
30 electrodes and wound dressings.

-14-

The adhesives with which this invention is concerned generally comprise, in addition to a crosslinked and/or entangled polymeric network, an aqueous plasticising medium and, optionally, at least one electrolyte, whilst the materials and processing methods used are normally chosen to provide a suitable balance of adhesive and electrical properties for the desired application. In particular, the type of water and its activity
5 together with the rheological properties of the hydrogels will generally be controlled to produce a balance of pressure sensitive adhesive properties and, when required, electrical properties. One preferred feature of the process used in carrying out the invention is that to achieve the desired adhesive and electrical properties the final amount of water required in the hydrogel is present in the formulation prior to gellation,
10 i.e. no water is removed from the hydrogel after manufacture and less than 10% during manufacture.

The monomer may, for example, be at least one hydrophilic monomer, or a mixture of at least one hydrophilic monomer with at least one hydrophobic monomer.

15

The hydrophilic monomer, when present, may for example be at least one ionic water-soluble monomer, or at least one non-ionic water-soluble monomer, or a mixture thereof. It is preferred that the aqueous reaction mixture should contain at least one ionic water-soluble monomer.

20

Where a hydrophobic monomer is present, the aqueous reaction mixture may be homogeneous or may be phase segregated, e.g. as an emulsion or microemulsion. Solubilising and/or emulsifying agents may be used to maintain the hydrophobic material in the desired state of solubilisation or emulsification in the aqueous reaction
25 mixture. Examples of a solubilised system are contained in our co-pending International PCT Patent Application No. PCT/GB00/ (Attorneys Reference DLB/67115/001) being filed simultaneously with the present application and claiming priority from our European Patent Application No. 99300740.0. The disclosures of the said co-pending International Patent Application and the said European Patent Application are
30 incorporated herein by reference.

The aqueous reaction mixture may suitably include further conventional agents such as at least one photoinitiator, at least one plasticiser or humectant, at least one electrolyte, at least one surfactant or any combination thereof.

The cross-linking agent may, for example, be at least one multi-functional cross-linking agent which is reactive with the monomer(s) present in the aqueous reaction mixture.

Particular examples of the components which may be present in the aqueous mixture will now be given.

10 *Monomers*

According to the present invention a 3-dimensional matrix, also referred to herein as a hydrogel, comprises a polymer which is cross-linked and/or entangled to the required degree. The polymer includes repeating units derived, for example, from vinyl alcohols, vinyl ethers, carboxy vinyl monomers, vinyl ester monomers, esters of carboxy vinyl monomers, vinyl amide monomers, anionic vinyl monomers, hydroxy vinyl monomers, cationic vinyl monomers containing amine or quaternary groups, N-vinyl lactam monomers, such as N-vinyl pyrrolidone, urethanes, acrylics such as (meth)acrylic acid and its alkali metal (e.g. Na, Li, K) or ammonium salts, (meth)acrylic acid ester derivatives (e.g. acrylic esters such as methyl, ethyl and butyl acrylates, 3-sulphopropyl acrylate alkali metal (e.g. Na, Li, K) or ammonium salts, polyethylene glycol (meth)acrylates, polyethylene glycol alkyl ether acrylate, 2-hydroxyethyl methacrylate, methoxydiethoxyethyl methacrylate or hydroxydiethoxyethyl methacrylate), acrylamides, mono- and di-N-substituted acrylamides (e.g. N,N-dimethylacrylamide, diacetone acrylamide or acryloyl morpholine), acrylonitrile, methacrylamides, sulphonated monomers such as acrylamide sulphonated monomers, for example 2-acrylamido-methylpropane sulphonic acid and its salts (e.g. Na or K salts), and acrylic (3-sulphopropyl) ester, and mixtures of all the foregoing, provided that the monomer or mixture is capable of forming a hydrogel on polymerisation.

-16-

For avoidance of doubt, the expression "polymer" and related expressions herein includes homopolymers and copolymers. The term "polymerise" is understood accordingly.

- As another alternative, the polymers may be block copolymer thermoplastic elastomers
- 5 such as ABA block copolymers such as styrene-olefin-styrene block copolymers or ethylene-propylene block copolymers. More preferably such polymers include hydrogenated grade styrol/ethylene-butylene/styrol (SEBS), styrene/isoprene/styrene (SIS), and styrol/ethylene-propylene/styrol (SEPS).
- 10 Particularly preferred monomers are acrylics, sulphonated monomers such as sulphonated acrylamides, mono- or di-N-alkylated acrylamides, vinyl alcohols, N-vinyl pyrrolidone and mixtures thereof.

- In a preferred embodiment of the invention the monomer comprises a water soluble
- 15 ionic acrylate based monomer selected for its ability to polymerise rapidly in water. Most preferably the ionic monomer comprises at least one of 2-acrylamido-2-methylpropane sulphonic acid or a substituted analogue thereof or one of its salts, for example, an alkali metal salt such as sodium, potassium or lithium salt. A particularly preferred example of the ionic monomer is 2-acrylamide-2-methylpropane sulphonic
- 20 acid, commonly known as NaAMPS, available commercially at present from Lubrizol as either a 50% aqueous solution (reference code LZ 2405) or a 58% aqueous solution (reference code LZ 2045A). The above referenced preferred ionic monomer and other suitable ionic monomers may optionally be used in combination with a polymerisable sulphonate or a salt, e.g. an alkali metal salt, such as a sodium, potassium or lithium salt
- 25 of acrylic (3-sulphopropyl) ester, commonly known as SPA. SPA (e.g. as potassium salt) is available commonly in the form of a pure solid from Raschig. The reaction mixture preferably comprises from about 5% to about 50%, preferably from about 10% to about 50%, and ideally from about 30% to about 50%, by weight of the reaction mixture, of the ionic monomer.

30

-17-

- In a further embodiment of the invention any nonionic water soluble monomer present may comprise any of the following either alone or in combination: at least one acrylamide, at least one mono- or di-N-alkylated acrylamide or an analogue thereof and at least one vinyl lactam. Preferably the nonionic water soluble monomer comprises at least one of a di-N-alkylacrylamide or an analogue thereof. The term "analogue" in this context refers to non ionic water soluble monomers containing an alkyl or substituted alkyl group linked to a carbon-carbon double bond via an amido or alkylamido (-CO.NH- or -CO.NR-) function. Examples of such analogues include diacetone acrylamide (N-1,1-dimethyl-3-oxobutyl-acrylamide), N-alkylated acrylamides, N,N-dialkylated acrylamides, N-vinyl pyrrolidone and acryloyl morpholine. N,N-dimethylacrylamide (NNDMA) and/or an analogue thereof is preferred. The reaction mixture preferably comprises from about 10% to about 50%, preferably from about 15% to about 30% and ideally from about 15% to about 25%, by weight of the reaction mixture, of any nonionic water soluble monomer.
- 15 The ratio of the ionic monomer to the nonionic monomer is preferably in the range from 30:1 to 1:10.

The total monomer content is ideally in the range from 10% to 70% by weight of the reaction mixture.

- 20 In one particularly preferred form of the invention, the monomer may comprise a mixture of at least one ionic water soluble monomer and at least one nonionic water soluble monomer. The ionic water soluble monomer may, for example, comprise 2-acrylamido-2-methylpropane sulphonic acid or a substituted analogue thereof or one of its salts, optionally in admixture with SPA or one of its salts, and the nonionic water soluble monomer may, for example, comprise NNDMA. Where the ionic water soluble monomer comprises a mixture of NaAMPS and SPA or one of its salts, it is generally preferred that a high ratio of NaAMPS to SPA, for example 70:30 and above, is used. Copolymers of such a monomer mixture with a suitable nonionic water soluble monomer, such as NNDMA, exhibit the required rheology. For further details of such bioadhesive compositions for use as skin adhesives, refer to our co-pending
- 25
- 30

International (PCT) Patent Application No. PCT/GB00/ (Attorneys
Reference DLB/67115/001) and European Patent Application No. 99300740.0, from
which it claims priority.

Plasticisers/Humectants

- 5 According to a preferred feature of the present invention the 3-dimensional adhesive
matrix also comprises a plasticiser or humectant, which is preferably a liquid at room
temperature. This material is selected such that the polymer may be solubilised or
dispersed within the plasticiser. For embodiments wherein irradiation cross linking is
to be carried out, the plasticiser must also be irradiation cross linking compatible such
10 that it does not inhibit the irradiation cross linking process of the polymer. The
plasticiser may be hydrophilic or hydrophobic.

- Suitable plasticisers include water, alcohols, polyhydric alcohols such as glycerol and
sorbitol, and glycols and ether glycols such as mono- or diethers of polyalkylene glycol,
15 mono- or diester polyalkylene glycols, polyethylene glycols (typically up to a molecular
weight of about 600), glycolates, glycerol, sorbitan esters, esters of citric and tartaric
acid, imidazoline derived amphoteric surfactants, lactams, amides, polyamides,
quaternary ammonium compounds, esters such phthalates, adipates, stearates,
palmitates, sebacates, or myristates and combinations thereof. Particularly preferred are
20 polyhydric alcohols, polyethylene glycol (with a molecular weight up to about 600),
glycerol, sorbitol, water and mixtures thereof.

- Typically the adhesive comprises a ratio polymer to plasticiser by weight of from 1:100
to 100:1, more preferably from 50:1 to 1:50. However, the exact amounts and ratios of
25 the polymer and plasticiser will depend to a large extent on the exact nature of polymer
and plasticisers utilised and can be readily selected by the skilled person in the art. For
example a high molecular weight polymer material will require a greater amount of
plasticiser than a low molecular weight polymer.

- 30 In a preferred embodiment of the invention the plasticiser comprises any of the
following either alone or in combination: at least one polymeric or non-polymeric

polyhydric alcohol (such as glycerol), at least one ester derived therefrom and/or at least one polymeric alcohol (such as polyethylene oxide). Glycerol is the preferred plasticiser. An alternative preferred plasticiser is the ester derived from boric acid and glycerol. The plasticiser is generally used to plasticise the hydrogel compositions in accordance with the invention and control adhesive and electrical properties, for electrically conducting hydrogels. When water is lost from the hydrogel both the adhesive and electrical properties may change deleteriously. The reaction mixture preferably comprises from about 10% to about 50% and preferably from about 15% to about 45%, by weight of the reaction mixture, of plasticiser (other than water).

10 *Water*

The reaction mixture preferably comprises up to about 40% (e.g. from about 3% to about 40%), by weight of the reaction mixture, of water. The water acts both as a solvent and as a further plasticiser. The activity of the water may be varied by changing its concentration and/or the presence of the other components for example monomer, plasticiser and electrolyte, if present. Control of the activity of the water will allow variation in adhesion, the extent of water uptake with increasing residence time on the skin and the electrical properties of the gel.

One preferred feature of the process used in carrying out the invention is that to achieve the desired adhesive and electrical properties the final amount of water required in the hydrogel is present in the formulation prior to gelation, i.e. less than about 5% water is removed from the hydrogel after manufacture and less than about 10% during manufacture.

The water activity of the hydrogel can be measured using impedance methods with devices such as the Rotronic AWVC (manufactured by Rotronic). The activity of water may also be determined by placing the hydrogel in environments of controlled humidity and temperature and measuring the changes in weight. The relative humidity (RH) at which the hydrogel does not change weight corresponds to the activity of water in the gel (%RH/100). The use of saturated salt solutions to provide the appropriate environmental conditions is well known. All hydrogels directly exposed to relative

-20-

humidities less than corresponding to the activity of water will be thermodynamically allowed to lose water. Exposure to greater relative humidities and the gel will gain weight. Water activity in the hydrogel is primarily dependent on the water content and the nature of the polymeric components and the way in which they are processed.

- 5 It has also been found that water activity influences the electrical properties. The higher the activity of water the lower the impedance (e.g. as measured at 10Hz).

Cross-Linkers

- 10 The cross-linking agent(s), if present, will provide the necessary mechanical stability and will assist in controlling the adhesive properties of the hydrogel. Any di- or multi-functional free radical cross-linking agent may be used. Typical crosslinkers include tripropylene glycerol diacrylate, ethylene glycol dimethacrylate, triacrylate, polyethylene glycol diacrylate (PEG400 or PEG600), methylene bis acrylamide.

15 *Surfactants*

Any compatible surfactant may be used. Nonionic, anionic and cationic surfactants are preferred. The surfactant ideally comprises any of the surfactants listed below either alone or in combination with other surfactants.

20 1. Nonionic Surfactants

- Suitable nonionic surfactants include, but are not limited to, those selected from the group consisting of the condensation products of a higher aliphatic alcohol, such as a fatty alcohol, containing about 8 to about 20 carbon atoms, in a straight or branched chain configuration, condensed with about 3 to about 100 moles, preferably about 5 to about 40 moles and most preferably about 5 to about 20 moles in ethylene oxide. Examples of such nonionic ethoxylated fatty alcohol surfactants are the Tergitol (TM) 15-S series from Union Carbide and Brij (TM) surfactants from ICI. 15-S surfactants include C₁₁-C₁₅ secondary alcohol polyethyleneglycol ethers. Brij (TM) 58 surfactant is polyoxyethylene (20) cetyl ether, and Brij (TM) 76 surfactant is polyoxyethylene (10) stearyl ether.

-21-

Other suitable nonionic surfactants include, but are not limited to, those selected from the group consisting of the polyethylene oxide condensates of one mole of alkyl phenol containing from about 6 to 12 carbon atoms in a straight or branched chain configuration, with about 3 to about 100 moles of ethylene oxide. Examples of nonionic surfactants are the Igepal (TM) CO and CA series from Rhone-Poulenc. Igepal (TM) CO surfactants include nonylphenoxy poly(ethyleneoxy) ethanols. Igepal (TM) CA surfactants include octylphenoxy poly(ethyleneoxy) ethanols.

Another group of usable nonionic surfactants include, but are not limited to, those selected from the group consisting of block copolymers of ethylene oxide and propylene oxide or butylene oxide.

Examples of such nonionic block copolymer surfactants are the Pluronic (TM) and Tetronic (TM) series of surfactants from BASF. Pluronic (TM) surfactants include ethylene oxide-propylene oxide block copolymers. Tetronic (TM) surfactants include ethylene oxide-propylene oxide block copolymers. The balance of hydrophobic and hydrophilic components within the surfactant together with the molecular weight are found to be important. Suitable examples are Pluronic L68 and Tetronic 1907. Particularly suitable examples are Pluronic L64 and Tetronic 1107.

Still other satisfactory nonionic surfactants include, but are not limited to, those selected from the group consisting of sorbitan fatty acid esters, polyoxyethylene sorbitan fatty acid esters and polyoxyethylene stearates. Examples of such fatty acid ester nonionic surfactants are the Span (TM), Tween (TM), and Myrj (TM) surfactants from ICI. Span (TM) surfactants include C_{12} - C_{18} sorbitan monoesters. Tween (TM) surfactants include poly(ethylene oxide) C_{12} - C_{18} sorbitan monoesters. Myrj (TM) surfactants include poly(ethylene oxide) stearates.

2. Anionic Surfactants

Anionic surfactants normally include a hydrophobic moiety selected from the group consisting of (about C_6 to about C_{20}) alkyl, alkylaryl, and alkenyl groups and an anionic

group selected from the group consisting of sulfate, sulfonate, phosphate, polyoxyethylene sulfate, polyoxyethylene sulfonate, polyoxyethylene phosphate and the alkali metal salts, ammonium salts, and tertiary amino salts of such anionic groups.

Anionic surfactants which can be used in the present invention include, but are not limited to, those selected from the group consisting of (about C₆ to about C₂₀) alkyl or alkylaryl sulfates or sulfonates such as sodium lauryl sulfate (commercially available as Polystep (TM) B-3 from Stepan Co.) and sodium dodecyl benzene sulfonate (commercially available as Siponate (TM) DS-10 from Rhone-Poulenc); polyoxyethylene (about C₆ to about C₂₀) alkyl or alkylphenol ether sulfates with the ethylene oxide repeating unit in the surfactant below about 30 units, preferably below about 20 units, most preferably below about 15 units, such as Polystep (TM) B-1 commercially available from Stepan Co., and Alipal (TM) EP110 and 115 from Rhone-Poulenc (about C₆ to about C₂₀) alkyl or alkylphenoxy poly(ethyleneoxy)ethyl mono-esters and di-esters of phosphoric acid and its salts, with the ethylene oxide repeating unit in the surfactant below about 30 units, preferably below about 20 units, most preferably below about 15 units, such as Gafac (TM) RE-510 and Gafac (TM) RE-610 from GAF.

3. Cationic Surfactants

Cationic surfactants useful in the present invention include, but are not limited to, those selected from the group consisting of quaternary ammonium salts in which at least one higher molecular weight group and two or three lower molecular weight groups are linked to a common nitrogen atom to produce a cation, and wherein the electrically-balancing anion is selected from the group consisting of a halide (bromide, chloride, etc), acetate, nitrite, and lower (e.g. C₁ to C₄) alkylsulfate (methosulfate etc). The higher molecular weight substituent(s) on the nitrogen is/are often (a) higher alkyl group(s), containing about 10 to about 20 carbon atoms, and the lower molecular weight substituents may be lower alkyl of about 1 to about 4 carbon atoms, such as methyl or ethyl, which may be substituted, as with hydroxy, in some instances. One or more of

-23-

the substituents may include an aryl moiety or may be replaced by an aryl, such as benzyl or phenyl.

In a particular preferred embodiment of the invention the surfactant comprises at least one propylene oxide/ethylene oxide block copolymer, for example such as that supplied
5 by BASF Plc under the trade name Pluronic L64. The reaction mixture preferably comprises from about 0.05% to about 10% and ideally from about 0.1% to about 5%, by weight of the reaction mixture, of surfactant.

The surfactant is believed to act to remove grease from the skin and to form the removed
10 grease into isolated pockets within the hydrogel without reducing the work of adhesion of the coating.

Lipid-Micellising Polymers

In a further form of the invention the reaction mixture may further comprises from about
15 0.1% to about 5% by weight of the reaction mixture of a lipid-micellising polymer, i.e. a so-called hypercoiling polymer. This polymer functions to micellise and remove the rolled up pockets of grease from the gel-skin interface.

This hypercoiling polymer has the capability of more effectively solvating the primary
20 surfactant micelles that contact hydrophobic skin contamination such as skin lipid or skin crème. The consequence of this functional role is that the work of adhesion between adhesive and skin is progressively less affected by the presence of either or both surfactant or hydrophobic skin contamination.

25 The hypercoiling polymer preferably comprises any of the following either alone or in combination: poly (maleic acid-styrene), poly (maleic acid-butyl vinyl ether), poly (maleic acid-propyl vinyl ether), poly (maleic acid-ethyl vinyl ether) and poly (acrylic acid-ethyl acrylate).

30 A particularly preferred example is an alternating copolymer of styrene and maleic acid.

Interpenetrants

Hydrogels based on interpenetrating polymer networks (IPN) are well known. The present invention is applicable to such systems. An IPN has been defined as a combination of two polymers, each in network form, at least one of which has been synthesised and/or crosslinked in the presence of the other. As will be appreciated, this combination will generally be a physical combination rather than a chemical combination of the two polymers. IPN systems may be described by way of example as follows:

Monomer 1 is polymerised and crosslinked to give a polymer which is then swollen with monomer 2 plus its own crosslinker and initiator.

If only one polymer in the system is crosslinked the network formed is called a semi-IPN. Although they are also known as IPN's, it is only if there is total mutual solubility that full interpenetration occurs. In most IPN's there is, therefore, some phase separation but this may be reduced by chain entanglement between the polymers. It has also been reported that semi IPN's can be made in the presence of carrier solvents (for example water in the case of hydrophilic components).

Polymerising and crosslinking water soluble monomers in the presence of water soluble polymers, water and polyhydric alcohols produces hydrogel materials with enhanced rheological and consequently adhesive properties.

Suitable water soluble polymers for the formation of semi IPN's include poly (2-acrylamido-2-methylpropane sulphonic acid) or one of its salts and its copolymers, poly (acrylic acid -(3-sulphopropyl) ester potassium salt), copolymers of NaAMPS and SPA, polyacrylic acid, polymethacrylic acid, polyethylene oxide, polyvinyl methyl ether, polyvinyl alcohol, polyvinylpyrrolidone, its copolymers with vinyl acetate, dimethylaminoethyl methacrylate, terpolymers with dimethylaminoethyl methacrylate and vinylcaprolactam, polysaccharides such as gum arabic, karaya gum, xanthan gum, guar gum, carboxymethyl cellulose (CMC), NaCMC, hydroxypropylmethyl cellulose (HPMC), hydroxyethyl cellulose (HEC) or combination thereof.

-25-

The amount of interpenetrant polymer used will be dependent on the mechanical and rheological properties required as well as on consideration of processing conditions. If the interpenetrant polymer used increases the viscosity of the pre-gel mix beyond 5000 centipoise, the monomers do not polymerise and crosslink on an acceptable time scale (should be less than 60 seconds, preferably less than 10 seconds). The viscosity depends on the nature of molecular weight of the interpenetrant and the nature of pre-gel processing.

Of the natural polysaccharides, gum arabic is usually preferred due to its cold water solubility and lesser effect on viscosity compared with, for example, karaya gum. A higher concentration of gum arabic than karaya may therefore be used if desired, enabling a wider control of hydrogel properties. The processing steps for assembling the pre-gel formulation can be critical with respect to the properties of the manufactured hydrogel. For a given formulation, if the components are assembled at 25°C and cured different electrical and adhesive properties are obtained compared to those that have been heated to 70°C. Whilst adhesive properties may be enhanced, electrical properties e.g. low frequency impedance, can be downgraded. Solutions containing natural polysaccharides become less opaque indicative of improved solubility. The activity of water in hydrogels prepared from heat treated pre-gels generally is lower than in non heat treated pre-gels.

20

Electrolytes

Any suitable electrolyte may be included in the bioadhesive composition, in an amount sufficient to provide or enhance electrical conductivity. Suitable electrolytes include water-soluble salts, particularly alkali metal salts such as sodium and potassium halide salts, most particularly sodium chloride or potassium chloride.

25

Other additives

Additional functional ingredients may also be incorporated in the hydrogels of this invention, including antimicrobial agents (e.g. citric acid, stannous chloride) and, for drug delivery applications, pharmaceutically active agents, the latter being designed to

30

-26-


be delivered either passively (e.g. transdermally) or actively (e.g. iontophoretically) through the skin.

Polymerisation with Cross-linking and/or Entanglement


The method of manufacture of the compositions of the invention generally involves free radical polymerisation and ideally would involve the use of photoinitiation or a combination of photoinitiation and thermal initiation. However, any free radical induced process of initiation may be used, for example Redox, thermal, electron beam and gamma or UV radiation. Preferably the reaction mixture comprises from 0.02% to 2%, and ideally from 0.02% to 0.2%, by weight of the reaction mixture of a photoinitiator. Preferably the reaction mixture comprises from 0.02% to 2%, and ideally from 0.02% to 0.2%, by weight of a thermal initiator. Preferred photoinitiators include any of the following either alone or in combination:

Type I- α -hydroxy-ketones and benzilidimethyl-ketals e.g. Irgacure 651. These are believed on irradiation to form benzoyl radicals that initiate polymerisation. Photoinitiators of this type that are preferred are those that do not carry substituents in the *para* position of the aromatic ring. Examples include Irgacure 184 and Darocur 1173 as marketed by Ciba Chemicals, as well as combinations thereof.

Photoinitiators of the following general formula are preferred:









where R_1 can be any of the following:- hydrogen, $\text{H}_3\text{C-S-}$,



-27-


R₁ is most preferably hydrogen.

R₂ can suitably be any of the following:-



R₂ is most preferably as follows:-

5



10

A particularly preferred photoinitiator is 1-hydroxycyclohexyl phenyl ketone; for example as marketed under the trade name Irgacure 184 by Ciba Speciality Chemicals.

Also preferred are Darocur 1173 (2-hydroxy-2-propyl phenyl ketone) and mixtures of Irgacure 184 and Darocur 1173.

15

-28-

In preparing bioadhesive compositions in accordance with the invention, the ingredients will usually be mixed to provide a reaction mixture in the form of an initial pre-gel aqueous based liquid formulation, and this is then converted into a hydrogel by a free radical polymerisation reaction. This may be achieved for example using conventional thermal initiators and/or photoinitiators or by ionizing radiation. Photoinitiation is a preferred method and will usually be applied by subjecting the pre-gel reaction mixture containing an appropriate photoinitiation agent to UV light after it has been spread or coated as a layer on siliconised release paper or other solid substrate. The incident UV intensity, at a wavelength in the range from 240 to 420nm, is ideally substantially 40mW/cm². The processing will generally be carried out in a controlled manner involving a precise predetermined sequence of mixing and thermal treatment or history.

The UV irradiation time scale should ideally be less than 60 seconds, and preferably less than 10 seconds to form a gel with better than 95% conversion of the monomers and for conversion better than 99.95% exposure to UV light less than 60 seconds and preferably less than 40 seconds is preferred. Those skilled in the art will appreciate that the extent of irradiation will be dependent on the thickness of the reaction mixture, concentration of photoinitiator and nature of substrate onto which the reaction mixture is coated and the source of UV.

These timings are for medium pressure mercury arc lamps as the source of UV operating at 100 W/cm. The intensity of UV between 240nm and 420nm reaching the surface of the substrate is at least 200mW/cm² as measured on a Solascope from Solatell. For a given lamp, UV intensity is a function of the operating power and distance of the reaction mixture from the UV source.

As already described above, however, the polymerisation with cross-linking and/or entanglement conditions may be selected, having regard to the diagnostic tan delta gradient, to achieve the desired skin adhesion properties according to the present invention.

-29-

It is noted that although the adhesives of this invention are normally prepared as sheets, coatings or laminates, other and non-limiting forms of preparation include fibres, strands pellets or particles.

- 5 The coating may be on a wide variety of substrates for example siliconised paper, polyester, metal foil, non-woven fabric, foam or mesh. The coating may also be integrated into gel. The thickness of the coating is preferably in the range from 0.03 mm to 2.0 mm. The gel may be laid down onto a substrate web via a slot die.

Applications

- 10 The adhesives described herein may be used in a range of skin contact applications either unsupported, or in the form of supported layers, membranes, composites or laminates. Biomedical skin electrodes and medical skin coverings are mentioned in particular.
- 15 Such medical skin coverings include tapes, bandages and dressings of general utility, wound healing and wound management devices; skin contacting, ostomy and related incontinence devices and the like. Other fields of application include pharmaceutical delivery devices, for the delivery of pharmaceuticals or other active agents to or through mammalian skin, optionally containing topical, transdermal or iontophoretic agents and
- 20 excipients. Particular bioadhesives may, for example, find application in buccal or gastrointestinal drug delivery systems. Non-limiting examples of penetration-enhancing agents include methyl oleic acid, isopropyl myristate, Azone ® Transcutol ® and N-methyl pyrrolidone.
- 25 It is preferred that the adhesives are supported as layers in use as biomedical skin electrodes or medical skin coverings.

- Biomedical skin electrodes typically comprise a flexible planar conductive member rendered skin-adhesive by the presence of a layer of a conductive bioadhesive
- 30 composition on the skin-directed face of the conductive member. The bioadhesive composition of the present invention may be used for this purpose, preferably with the

inclusion of an electrolyte such as potassium chloride to enhance electrical conductivity. The conductive member may suitably include a synthetic material such as a polyester film or polyurethane foam and may include synthetic and/or natural fibres. The conductive member will typically include a finely divided conductivity enhancer such as a metal (e.g. as a finely divided powder or the like) or carbon powder. A metallised interface (e.g. silver/silver chloride) may suitably be provided between the conductive member and the adhesive layer, again to enhance conductivity.

Biomedical skin electrodes may be adapted to be electrically connected to an electrical diagnostic, therapeutic or electrosurgical apparatus, or to earth, via a connecting lead. The lead may be separably connectable to the electrode, or may be fixedly connected to the electrode.

An electrode adapted for separable connection to the connecting lead may, for example, include an electrically conductive tab which extends from the planar conductive member and which can be received in a suitably configured conductive clamp or clip connected to the connecting lead, e.g. a clip having sprung jaws which grip the tab and thereby establish the electrical connection between the electrode and the electrical apparatus or earth.

An alternative electrode adapted for separable connection to the connecting lead may, for example, include a metal or metal-plated stud or eyelet protruding through the flexible planar conductive member, the stud or eyelet being in electrical connection with the bioadhesive composition, suitably via a snap-fitted locking piece which locks the stud or eyelet to the conductive member by sandwiching at least a portion of the conductive member between the stud or eyelet and the snap-fitted locking piece. In this embodiment, the clip provided on the lead will be configured to engage with the stud or eyelet or alternatively a snap-fit device may be provided on the lead, which engages with the stud or eyelet.

An electrode having a fixed connecting lead may, for example, include a conductive lead having an insulating sheath which is configured to leave a bare end of a conductive

-31-

lead core embedded in the planar conductive member. The end of the conductive lead may be electrically connected to a current distribution member embedded in the planar conductive member, e.g. as described in EP-A-0012402, the disclosure of which is incorporated herein by reference.

- 5 Any electrical lead connecting the biomedical skin electrode to an electrical diagnostic, therapeutic or electrosurgical apparatus, or to earth, may itself be arranged in two or more releasably connected portions if convenient.

- 10 The layer of bioadhesive composition on the biomedical skin electrode may suitably be protected before use by a protective release layer. For use, the release layer is removed and the bioadhesive composition of the invention - on the skin-directed face of the conductive member - is applied to the skin of the patient, whereby the electrode becomes attached to the skin.

- 15 The discussion above of various possible types of skin electrode is non-limiting. The bioadhesive composition of the present invention may be employed with all shapes and configurations of skin electrodes. In addition to the prior art references cited above, describing specific types of skin electrode, reference is also directed to WO-A-97/24149 (Minnesota Mining and Manufacturing Company), the disclosure of which is
20 incorporated herein by reference, and particularly Figures 1 to 5 thereof and the associated description, which illustrate some of the conventional shapes and configurations of biomedical skin electrode in which the bioadhesive composition of the present invention may be used. These illustrated electrodes are separable from a connector lead which electrically connects the conductive medium to the electrical
25 equipment or to earth.

- When the hydrogels are intended for use in conjunction with Ag/AgCl medical electrodes, chloride ions are required to be present in order for the electrode to function. Potassium chloride and sodium chloride are commonly used. However any compound
30 capable of donating chloride ions to the system may be used, for example, lithium chloride, calcium chloride, ammonium chloride. The amount that should be added is

dependent on the electrical properties required and is typically 0.2% to 8% and preferably 1% to 7% by weight.

The main electrical property of interest is the impedance. Performance standards have been drawn up by the American Association of Medical Instruments (AAMI). In
5 sensing electrode applications the electrodes, consisting of the adhesive and a suitable conductive support, are placed in pairs, adhesive to adhesive contact. The conductive support frequently has a Ag/AgCl coating in contact with the adhesive. The measured impedance is dependent on both the quality of the Ag/AgCl coating and the adhesive. In this configuration the adhesive must contain chloride ions. The concentration of
10 chloride ions influences the impedance such that increasing the concentration can lower impedance. It would be anticipated that the activity of the ions (as opposed to the concentration) would be important in determining impedance, but in practice the determination of ion activity in these systems is not a trivial matter. In designing the hydrogel for lowest impedance as measured under the AAMI standard, allowance must
15 be given for the amount and activity of water. These factors will control the effective ion activity and hence the amount of chloride available for participating in the electrochemistry of the system. Hydrogels with lower chloride concentration but higher water activity have lower impedances.

20 A further application is in the field of medical skin coverings.

Medical skin coverings are useful for treatment of mammalian skin or mammalian skin openings, particularly against the possibility of infection and also for the transmission of moisture vapour and exudates from the skin. The medical skin coverings generally
25 comprise a backing material onto which a layer of the bioadhesive composition of the invention is coated, the bioadhesive composition being protected before use by a protective release layer. The bioadhesive composition may, for example, include antimicrobial agents. For use, the release layer is removed and the bioadhesive composition of the invention is applied to the skin of the patient as part of a medical
30 tape, a wound dressing, a bandage of general medicinal utility, or other medical device having moisture absorbing properties.

-33-

The bioadhesive composition layer may be coated on a layer of backing material selected from a range of suitable backing materials for use as medical tapes, dressings, bandages and the like. Suitable backing materials include those disclosed in US Patents Nos. 3645835 and 4595001, the disclosures of which are incorporated herein by reference. In addition to these prior art references, reference is also directed to WO-A-
5 97/24149, and particularly Figure 6 thereof and the associated description, which illustrates a conventional configuration of a medical skin covering in which the bioadhesive composition of the present invention may be used.

Examples of the Invention

10 The invention will be further described without limitation, with reference to the following Experiments, Examples and Test Methods.

Experiment A - Identification of a Diagnostic Tan Delta Minimum

The formulation detailed below was coated onto polyurethane foam (EV1700X from
15 Caligen) at a coat weight of 0.8 to 1.6kg per square meter and cured by exposure to ultraviolet radiation emitted from a medium pressure mercury arc lamp operating at 100 W/cm power for 10 seconds.

Example 1

20 Mix 6.0g of Irgacure 184 with 20g IRR280(PEG400 diacrylate) from UCB (Solution A). To 0.07g of Irgacure 184 add 23.5g of NNDMA and stir for one hour (keep container covered from light). Add 30g of glycerol to this and stir for 5 minutes, followed by 40g of NaAMPS (58% solution). Stir for another 5 minutes. Add 0.13g of Solution A and stir the whole formulation for 1 hour before use.

25

Table 1

Effect of water uptake on peel adhesion on dry skin for the formulation in Example 1.

30

-34-

Subject 1

5	% Water uptake	Peel Adhesion (N/cm)
	0	1.8
	9	2.2
	10	2.3
	24	1.6

Subject 2

10	% Water uptake	Peel Adhesion (N/cm)
	0	1.6
	9	2.9
	11	2.5
	12	2.6

Peel Adhesion Method

- 15 This is a method to determine the peel strength required of adhered hydrogel to the skin of two male subjects of different ethnic origin. The skin is tested "dry" (i.e. normal to the subject) as described next.

Equipment

20	Scissors	Convenient source
	Standard ruler	Convenient source
	Compression weight	5.0 kg, diameter 130mm
	Polyester Film	PET 23 μ available from EFFEGIDI
	Transfer Adhesive	S.p.A.43052 Colomo, Italy
25		3M 1524 available from 3M Italia
		S.p.A. 20090 Segrate, Italy
	Stop Watch	Convenient source
30	Tensile Tester	Instron mod: 6021 (or equivalent)

Test procedureA) Tensile Tester Peel Settings:-

35	Load cell	10N
	Test Speed	1000 mm/min

-35-

Clamp to Clamp

Distance 25mm

Pre Loading 0.2N

Test Path "LM" 50mm

Measure variable F average (N) in "LM"

5

B) Sample preparation

1. Each test specimen should be prepared individually and tested immediately.
2. Prepare rectangular adhesive samples 100mm \pm 2 length and 25.4mm width.
- 10 3. The specimen is placed into an oven at 37°C and at 85% humidity. The time of exposure is dependant on the degree of water uptake required. The sample is then removed from the oven and the steps 4 to 6 are carried out.
4. Attach adhesive specimen to the forearm within marked area with light pressure.
5. Gently roll the compression weight down the forearm, on the adhesion sample.
- 15 6. Remove the weight and test after 1 and 10 minutes by attaching one end of the specimen into the upper jaws of an adhesion testing machine at an initial angle of 90°.

The rheology of the compositions of the invention will be further exemplified with
 20 reference to the accompanying drawings in which:

Figure 1 shows schematic tan delta profiles for hydrogels exhibiting adhesion loss (comparison "Example A") and adhesion increase (Example 1) on water uptake;

25 Figure 2 shows plots of G' , G'' and tan delta against frequency for the freshly made hydrogel of above Example 1;

Figure 3 shows plots of G' , G'' , and tan delta against frequency for the freshly made hydrogel of above Example 1 after 7% water uptake.

30

Comparison Example A

Mix 6.0 g of Irgacure 184 with 20 g IRR280 (PEG 400 diacrylate) from UCB (Solution A). To 23 g of glycerol, 10 g of an ethylene/vinyl acetate copolymer emulsion (50% solids) (product of Harco Chemicals marketed under the trade name DM137) are added,
 5 followed by 40 g of NaAMPS (58% solution) and 20 g of the potassium salt of 3-sulpho-propyl acrylate (SPA) with stirring. To this solution there are added 0.15 g of Solution A. The final solution is stirred for one hour and coated and cured as for Example 1 above.

- 10 As shown in Figure 2, the tan delta curve exhibits a minimum at a frequency of about 50 rad/s, i.e. a single (zero gradient) minimum over the diagnostic range 0.01 to 100 rad/s. As shown in Figure 3, this minimum is generally lost as water uptake proceeds.

15 Experiment B - Identification and Adjustment of a Diagnostic Tan Delta Gradient

Examples 2 and 3 Formulations (all figures are weights in grams)

Example	NaAMPS (58%)	SPA	Polyethylene Glycol (MWt 400)	KCl	IRR 280	Irgacure 184
20 2A	57	10	20	3	0.062	0.02
2B	57	10	20	3	0.069	0.02
2C	57	10	20	3	0.077	0.02
2D	57	10	20	3	0.085	0.02
25 2E	57	10	20	3	0.092	0.02
2F	57	10	20	3	0.1	0.02
2G	57	10	20	3	0.138	0.02
	NaAMPS (50%)		Glycerol		IRR 210	Irgacure 184
3A	68.5	0	31.5	0	0.062	0.02
3B	68.5	0	31.5	0	0.077	0.02
30 3C	68.5	0	31.5	0	0.092	0.02
3D	68.5	0	31.5	0	0.108	0.02
3E	68.5	0	31.5	0	0.115	0.02

-37-

Method of preparation, Example 2:

1. 0.02g of Irgacure 184 is dissolved in relevant weight of a PEG400 diacrylate crosslinker (IRR 280, from UCB) and is designated Solution A.
- 5 2. NaAMPS (58% solution) is mixed with SPA, KCl and polyethyleneglycol (PEG400) using a mechanical stirrer for at least half an hour and then the appropriate amount of Solution A is added. The solution is stirred for a further minimum of one hour before it is extruded from a slot die (coat weight approximately 1kg per square meter) onto release paper and cured by passing
10 under 3 100W/cm medium pressure mercury arc lamps at a speed of 7m/minute.

Method of preparation, Example 3:

- 15 1. 0.02g of Irgacure 184 is dissolved in relevant weight of a triacrylate crosslinker (IRR 210) and is designated Solution A.
- 20 2. NaAMPS (50% solution) is mixed with glycerol using a mechanical stirrer for at least half an hour and then the appropriate amount of Solution A is added. The solution is stirred for a further minimum of one hour before it is extruded from a slot die (coat weight approximately 1kg per square meter) onto release paper and cured by passing under 3 100W/cm medium pressure mercury arc lamps at a speed of 7m/minute.

25 Circular samples of each composition (25mm diameter) are then cut and placed between parallel plates of a Rheometrics SR5 Rheometer (controlled stress parallel plate rheometer).

The results of the tan delta measurements are shown as follows.

- 30 Figures 4A to 4G show plots of G' , G'' and tan delta against frequency for the freshly made hydrogels of Examples 2A to 2G respectively.

Figures 5A to 5E show plots of G' , G'' and $\tan \delta$ against frequency for the freshly made hydrogels of Examples 3A to 3E respectively.

Figure 6 shows plots of $\tan \delta$ gradient v. ratio M:XL (mole M:weight XL), using data from Figures 4 and 5, the respective Figures 4A to 4F and 5A to 5E being noted at the points plotted.

In Figures 4A through to 4G, the variation in $\tan \delta$ (top curve, marked by diamond shapes) can be clearly seen as the amount of cross-linking agent (and thereby the extent of cross-linking in the polymer) increases. The diagnostic portion of the frequency range 0.01 to 300 rad/s is here the sub-range 1 to about 4 rad/s. (Note that each axis follows a logarithmic scale). Within the range 0.01 to 300 rad/s a single minimum (A) can be seen in Figure 4A, which disappears gradually and is lost by figure 4G. Moreover, the negative slope of the $\tan \delta$ gradient of Figure 4A in the diagnostic frequency range 1 to about 4 rad/s (i.e. frequencies below the frequency of the minimum A) is also gradually lost as the amount of cross-linking agent (and thereby the extent of cross-linking in the polymer) increases. By Figure 4G there is no discernable slope to the $\tan \delta$ gradient in the diagnostic range 1 to about 4 rad/s, i.e. the gradient has reduced to zero.

In Figures 5A through to 5E, the variation in $\tan \delta$ (top curve, marked by diamond shapes) can be clearly seen as the amount of cross-linking agent (and thereby the extent of cross-linking in the polymer) increases. The diagnostic portion of the frequency range 0.01 to 300 rad/s is here the sub-range 1 to about 5 rad/s (note again that each axis follows a logarithmic scale). Within this diagnostic portion, an increase in the extent of cross-linking (Figures 5D and 5E) results in the appearance of a positive slope of $\tan \delta$ against frequency. Thus, within the range 0.01 to 300 rad/s the more cross-linked compositions exhibit a single maximum (B) at a frequency of about 5 rad/s, a feature characteristic of water-unstable compositions which will lose adhesion to a substantial degree on uptake of water from the surrounding environment.

A comparison of the individual plots of G' and G'' in Figures 5A through to 5E shows that there is a substantial change in the gradient of the G' plot against frequency, the low frequency values of G' being markedly reduced in the polymers having lower degree of cross-linking. This effect is observed to a lesser extent in the example shown in Figures 4A through to 4G.

5

Figure 6 shows a plot of $\tan \delta$ v. ratio M:XL (ratio expressed as moles of monomer M to weight of cross-linking agent XL) within the range 1 to 4. Data from Figures 4A to 4G and 5A to 5E were used to construct Figure 6. The upper curve relates to Figures 5A to 5E and the lower curve relates to Figures 4A to 4G.

10

It can be clearly seen that the $\tan \delta$ gradient in the respective diagnostic portion of the frequency range (1 to 4 rad/s for Figures 4A to 4G and 1 to 5 rad/s for Figures 5A to 5E) crosses the zero gradient from a negative gradient to a positive gradient as the amount of cross-linking agent is increased (i.e. the ratio M:XL is reduced).

15

Experiment C - Characterisation of Tan Delta Curves for Selected Hydrogels

A range of hydrogel compositions is prepared and the $\tan \delta$ gradient in the diagnostic frequency region determined. From this, each hydrogel is characterised by whether or not it exhibits a $\tan \delta$ minimum or negative slope in the diagnostic portion of the frequency range 0.01 to 300 rad/s. By selecting appropriate levels of cross-linking agent and photoinitiator, the $\tan \delta$ minimum or negative slope can be arranged to be present or absent, as desired.

Examples 4 to 13 Formulations (all figures are parts by weight)

Example No.	4	5	6	7	8	9	10	11	12	13
Glycerol	33	33	33	33	33	33	33	33	33	33
Sodium AMPS	39	39	19.3	19.3	19.3	19.3				
N,N-Dimethyl acrylamide			19.3	19.3					33.5	33.5
3- sulphopropyl acrylate, potassium salt							39	39		
Diacetone acrylamide					19.3	19.3				
Sodium vinyl sulphonate									8	8
Water	28	28	28	28	28	28	28	28	25.5	25.5
Irgacure 184/IRR280	0.06	0.25	0.06	0.18	0.06	0.18	0.06	0.18	0.06	0.18

Method of Preparation, Examples 4 to 13

1. 6 parts of Irgacure 184 are dissolved in 20 parts of a PEG 400 diacrylate crosslinker (IRR 280 from UCB) and the resulting solution is designated Solution A.

2. Monomers, water and glycerol are mixed in the proportions indicated in the table above using a mechanical stirrer for at least half an hour and then the appropriate amount of Solution A is added. The solution is stirred for a further minimum of one hour before being extruded from a slot die (coat weight approximately 1 kg per square meter) onto release paper and cured by passing under 3 100W/cm medium pressure mercury arc lamps at a speed of 7m/minute.

Results:

As a result of tan delta measurements analagously to those described in connection with Experiment B above, the formulations are characterised as follows.

5	Example No.	4	5	6	7	8	9	10	11	12	13
10	Tan Delta Minimum or negative slope	Yes	No	Yes	No	Yes	No	Yes	No	Yes	No

As will be seen, the invention presents a number of different aspects and it should be understood that it embraces within its scope all novel and inventive features and aspects herein disclosed, either explicitly or implicitly and either singly or in combination with one another. Also, many detailed modifications are possible and, in particular, the scope of the invention is not to be construed as being limited by the illustrative example(s) or by the terms and expressions used herein merely in a descriptive or explanatory sense.

CLAIMS

1. A bioadhesive composition for use as a skin adhesive, the composition formed by polymerising with cross-linking and/or entanglement an aqueous reaction mixture comprising at least one monomer dissolved or suspended therein and capable of forming a hydrogel on polymerisation, optionally at least one cross-linking agent for the monomer, and water, said composition having an elastic modulus (G') and a viscous modulus (G''), wherein the degree of polymerisation and/or the degree of cross-linking and/or entanglement are selected to control the skin adhesion properties of the bioadhesive composition having regard to the rate of change of $\tan \delta$ ($G'' \div G'$) against frequency in a diagnostic portion of the frequency range 0.01 to 300 rad/s.
2. A bioadhesive composition as claimed in claim 1, wherein the desired degree of polymerisation and/or the degree of cross-linking and/or entanglement in the polymerised composition is achieved by selection of the amount of monomer in the aqueous reaction mixture, the amount of any cross-linking agent present in the aqueous reaction mixture, and/or the reaction conditions for the polymerisation with cross-linking and/or entanglement.
3. A bioadhesive composition as claimed in claim 1 or claim 2, wherein the diagnostic portion of the frequency range is less than about 100 rad/s.
4. A bioadhesive composition as claimed in claim 3, wherein the diagnostic portion of the frequency range is less than about 30 rad/s.
5. A bioadhesive composition as claimed in claim 3, wherein the diagnostic portion of the frequency range is less than about 10 rad/s.
6. A bioadhesive composition as claimed in any of the preceding claims, wherein the measurement of elastic modulus and viscous modulus is carried out at a temperature of about 37°C.

7. A bioadhesive composition as claimed in claim 2, wherein a cross-linking agent is present in the aqueous reaction mixture and the relative amount of monomer and cross-linking agent is selected to achieve the desired degree of cross-linking.
- 5 8. A bioadhesive composition as claimed in any of the preceding claims, wherein a cross-linking agent is present in the aqueous reaction mixture and the molar ratio of monomer(s) to cross-linking agent(s) is selected within the range of about 10,000:1 to about 200:1.
- 10 9. A bioadhesive composition as claimed in claim 2, wherein the reaction conditions for the polymerisation with cross-linking and/or entanglement are selected by controlling one or more of the following aspects of the polymerisation reaction:
- 15 (a) the reactivity of the monomer(s) and the number of polymerisable functions per molecule;
- (b) the reactivity of the cross-linking agent(s) and the number of reactive functions per molecule;
- 20 (c) the presence of any polymerisation inhibitor(s);
- (d) the presence of any chain-transfer agent(s);
- 25 (e) the weight fraction of monomer(s) and cross-linking agent(s) in the reaction mixture;
- (f) the initiation efficiency; and
- 30 (g) the reaction time.

10. A bioadhesive composition as claimed in any of the preceding claims, wherein the monomer comprises at least one hydrophilic monomer, or a mixture of at least one hydrophilic monomer with at least one hydrophobic monomer.
- 5 11. A bioadhesive composition as claimed in claim 11, wherein the hydrophilic monomer comprises at least one ionic water-soluble monomer, or at least one non-ionic water-soluble monomer, or a mixture of any two or more thereof.
- 10 12. A bioadhesive composition as claimed in any of the preceding claims, wherein the monomer comprises (meth)acrylic acid, alkali metal or ammonium salts thereof, (meth) acrylic acid esters, acrylamides, sulphonated acrylamides, mono- or di-N-alkylated acrylamides, vinyl alcohols, N-vinyl pyrrolidone or a mixture of any two or more thereof.
- 15 13. A bioadhesive composition as claimed in claim 12, wherein the monomer comprises 2-acrylamido-2-methylpropane sulphonic acid, an analogue thereof or a salt thereof.
- 20 14. A bioadhesive composition as claimed in claim 13, wherein acrylic (3-sulphopropyl) ester or a salt thereof is further present as an additional monomer.
- 25 15. A bioadhesive composition as claimed in any preceding claim, wherein the monomer comprises 3-sulphopropyl acrylate, a salt of 3-sulphopropyl acrylate, diacetone acrylamide, N,N-dimethylacrylamide, N-vinyl pyrrolidone, acryloyl morpholine or a mixture of any two or more thereof.
- 30 16. A bioadhesive composition as claimed in any of the preceding claims, wherein the aqueous reaction mixture further includes at least one photoinitiator, at least one plasticiser, at least one humectant (other than water), at least one electrolyte, at least one surfactant, or a mixture of any two or more thereof.

-45-

17. A bioadhesive composition as claimed in claim 16, characterised in that said plasticiser comprises any of the following either alone or in combination: at least one polyhydric alcohol, at least one ester derived from polyhydric alcohol and at least one polymeric alcohol.
- 5 18. A bioadhesive composition as claimed in claim 16, characterised in that said plasticiser comprises at least one of glycerol and an ester derived from boric acid and glycerol.
- 10 19. A bioadhesive composition as claimed in claim 16, characterised in that the bioadhesive composition comprises from about 15% to about 45%, by weight of the reaction mixture of said plasticiser (other than water).
- 15 20. A bioadhesive composition as claimed in claims 16, characterised in that the reaction mixture comprises from about 0.1% to about 5%, by weight of the reaction mixture, of said surfactant.
21. A bioadhesive composition as claimed in claim 16, characterised in that said surfactant comprises one or more non ionic surfactants.
- 20 22. A bioadhesive composition as claimed in claim 16, characterised in that the surfactant comprises one or more anionic surfactants.
23. A bioadhesive composition as claimed in claim 16, characterised in that the surfactant comprises one or more cationic surfactants.
- 25 24. A bioadhesive composition as claimed in claim 16, characterised in that the surfactant comprises at least one propylene oxide/ethylene oxide block copolymer.
- 30 25. A bioadhesive composition as claimed in any of the preceding claims, in that the reaction mixture further comprises at least one lipid micellising polymer.

26. A bioadhesive composition as claimed in claim 25, characterised in that the reaction mixture comprises from about 0.1% to about 5%, by weight of the reaction mixture, of lipid micellising polymer.
- 5 27. A bioadhesive composition as claimed in claim 25 or claim 26, characterised in that the lipid micellising polymer comprises any of the following either alone or in combination: poly (maleic acid-styrene), poly (maleic acid-butyl vinyl ether), poly (maleic acid-propyl vinyl ether), poly (maleic acid-ethyl vinyl ether) and poly (acrylic acid-ethyl acrylate).
- 10 28. A bioadhesive composition as claimed in any of claims 25 to 27, characterised in that the lipid micellising polymer comprises an alternating copolymer of styrene and maleic acid.
- 15 29. A bioadhesive composition as claimed in claim 10, characterised in that the reaction mixture comprises from about 1% to about 15%, by weight of the reaction mixture, of said hydrophobic monomer, when present.
- 20 30. A bioadhesive composition as claimed in claim 10, characterised in that said hydrophobic monomer, when present, comprises any of the following either alone or in combination: n-butyl acrylate, n-butyl methacrylate, a hexyl acrylate, iso-octyl acrylate, isodecyl acrylate, ethoxyethyl acrylate, tetrahydrofurfuryl acrylate, vinyl propionate, and vinyl butyrate.
- 25 31. A bioadhesive composition as claimed in claim 10, characterised in that the hydrophobic monomer, when present, comprises at least one of ethoxy ethyl acrylate or butyl acrylate.
- 30 32. A bioadhesive composition as claimed in claim 10, characterised in that the reaction mixture from about 3% to about 20%, by weight of the reaction mixture, of said hydrophobic polymer, when present.

33. A bioadhesive composition as claimed in claim 10, characterised in that the said hydrophobic polymer, when present, comprises any of the following either alone or in combination: vinylacetate dioctyl maleate copolymer or ethylene vinylacetate copolymer.
- 5
34. A bioadhesive composition as claimed in any of the preceding claims, wherein the polymerisation is a free radical polymerisation.
35. A bioadhesive composition as claimed in claim 34, wherein the free radical polymerisation is performed in the presence of a photoinitiator.
- 10
36. A bioadhesive composition as claimed in claim 35, wherein the photoinitiator comprises 1-hydroxycyclohexyl phenyl ketone, 2-hydroxy-2-propyl phenyl ketone or a mixture thereof.
- 15
37. A bioadhesive composition as claimed in any of the preceding claims, characterised in that the composition provides adhesion on dry skin at no less than 0.5 N/cm.
- 20
38. A bioadhesive composition as claimed in any preceding claim, when exhibiting a negative rate of change of tan delta against frequency in at least part of the frequency range 0.01 to 100 rad/s.
39. A bioadhesive composition as claimed in claim 38, when exhibiting a negative rate of change of tan delta against frequency in at least part of the frequency range 0.01 to 30 rad/s.
- 25
40. A bioadhesive composition as claimed in claim 38 or 39, when exhibiting water stability as herein defined.
- 30

-48-

41. A bioadhesive composition as claimed in any of claims 1 to 37, when exhibiting a continuously substantially zero rate of change of tan delta against frequency in at least part of the frequency range 0.01 to 100 rad/s.
- 5 42. A bioadhesive composition as claimed in any of claims 1 to 37, when exhibiting a continuously substantially zero rate of change of tan delta against frequency in at least part of the frequency range 0.01 to 30 rad/s.
- 10 43. A bioadhesive composition as claimed in any of claims 1 to 37, when exhibiting a positive rate of change of tan delta against frequency in at least part of the frequency range 0.01 to 100 rad/s.
- 15 44. A bioadhesive composition as claimed in any of claims 1 to 37, when exhibiting a positive rate of change of tan delta against frequency in at least part of the frequency range 0.01 to 30 rad/s.
45. A bioadhesive composition as claimed in claim 43 to 44, when exhibiting water instability as herein defined.
- 20 46. A bioadhesive composition as claimed in any preceding claim, when exhibiting a zero rate of change of tan delta against frequency at only one point in the frequency range 0.01 to 300 rad/s.
- 25 47. Use of a bioadhesive composition as claimed in any preceding claim, in a biomedical skin electrode or in a wound dressing.
48. A method for preparing a bioadhesive composition for use as a skin adhesive, the method comprising:
- 30 (a) forming an aqueous reaction mixture comprising at least one monomer dissolved or suspended therein and capable of forming a hydrogel on

-49-

polymerisation, optionally at least one cross-linking agent for the monomer, and water; and

- (b) polymerising with cross-linking and/or entanglement the aqueous reaction mixture,

5 wherein the degree of polymerisation and/or the degree of cross-linking and/or entanglement are selected to control the skin adhesion properties of the bioadhesive composition having regard to the rate of change of $\tan \delta$ ($G'' \div G'$) against frequency in a diagnostic portion of the frequency range 0.01 to 300 rad/s, where G'' is the viscous modulus of the bioadhesive composition and G' is the elastic modulus of the bioadhesive composition.

10 49. A method as claimed in claim 48, for preparing a bioadhesive composition according to any of claims 2 to 46.

15 50. A method for controlling the skin adhesion properties of a bioadhesive composition for use as a skin adhesive, the method comprising polymerising with cross-linking and/or entanglement an aqueous reaction mixture comprising at least one monomer dissolved or suspended therein and capable of forming a hydrogel on polymerisation, optionally at least one cross-linking agent for the monomer, and water; wherein the reaction is conducted so that the degree of polymerisation and/or the degree of cross-linking and/or entanglement are selected to control the skin adhesion properties of the bioadhesive composition having regard to the rate of change of $\tan \delta$ ($G'' \div G'$) against frequency in a diagnostic portion of the frequency range 0.01 to 300 rad/s, where G'' is the viscous modulus of the bioadhesive composition and G' is the elastic modulus of the bioadhesive composition.

25 51. A method as claimed in claim 50, for controlling the skin adhesion properties of a bioadhesive composition according to any of claims 2 to 46.

30




FIG. 1

2 / 9




FIG. 2




FIG. 3

SUBSTITUTE SHEET (RULE 26)

3 / 9




FIG. 4A




FIG. 4B

SUBSTITUTE SHEET (RULE 26)

4 / 9




FIG. 4C




FIG. 4D

SUBSTITUTE SHEET (RULE 26)

5 / 9




FIG. 4E




FIG. 4F

SUBSTITUTE SHEET (RULE 26)

6 / 9




FIG. 4G




FIG. 5A

SUBSTITUTE SHEET (RULE 26)

7 / 9




FIG. 5B




FIG. 5C

SUBSTITUTE SHEET (RULE 26)

8 / 9




FIG. 5D





FIG. 5E

SUBSTITUTE SHEET (RULE 26)



INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 00/00304

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61L15/58 A61L24/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61L A61F C09J

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 855 190 A (PROCTER & GAMBLE) 29 July 1998 (1998-07-29) page 4, line 50 -page 7, line 29	1-12, 15-25, 27-29, 32, 34, 35, 37-51
X	US 5 173 302 A (BARTLETT TERESE A ET AL) 22 December 1992 (1992-12-22) abstract column 2, line 6 - line 47 column 3, line 18 - line 62 examples 1-4 ----- -/-	1-20, 29-32, 34-51

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

8 May 2000

Date of mailing of the international search report

18/05/2000

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Menidjel, R

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 00/00304

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
------------	--	-----------------------

X	<p>EP 0 676 457 A (GRAPHIC CONTROLS CORP) 11 October 1995 (1995-10-11)</p> <p>page 4, line 40 -page 5, line 49 page 7, line 27 -page 8, line 2 tables 1-6</p>	<p>1-18, 20-23, 29-32, 34,35, 37-51</p>
---	---	---

X	<p>US 5 670 557 A (DIETZ TIMOTHY M ET AL) 23 September 1997 (1997-09-23)</p> <p>column 20, line 5 - line 54 column 24, line 65 -column 25, line 48 column 28, line 62 -column 29, line 39 examples 1-7</p>	<p>1-12, 16-23, 29-32, 34-51</p>
---	--	--

X	<p>EP 0 012 402 A (MEDTRONIC INC) 25 June 1980 (1980-06-25)</p> <p>abstract page 2, line 4 - line 15 examples 1-25</p>	<p>1-12, 16-23, 29-51</p>
---	--	-----------------------------------

E	<p>WO 00 06214 A (MUNRO HUGH SEMPLE ;FIRST WATER LTD (GB); YASIN MOHAMMED (GB)) 10 February 2000 (2000-02-10) page 5, line 21 -page 6, line 14 page 9, line 18 -page 10, line 26 page 12, line 11 - line 25 examples 1-10</p>	<p>1-24, 29-51</p>
---	---	------------------------

A	<p>VAMVAKAKI M ET AL: "Synthesis of novel block and statistical methacrylate-based ionomers containing acidic, basic or betaine residues" POLYMER,GB,ELSEVIER SCIENCE PUBLISHERS B.V, vol. 39, no. 11, 1 January 1998 (1998-01-01), pages 2331-2337, XP004111299 ISSN: 0032-3861 page 2331, left-hand column, paragraph 1 -page 2332, left-hand column, paragraph 3</p>	<p>1,25-28</p>
---	---	----------------

INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB 00/00304

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see further information sheet
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/GB 00 00304

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1-8, 37-46, 48-51 relate to a product/method defined by reference to a desirable characteristic or property, namely to the rate of change of tan delta (G''/G') against frequency in a diagnostic portion of the frequency range 0.01 to 300 rad/s at 37°C.

The ratio of G'' to G' (G''/G') is referred to as tan delta, G' corresponding to the elastic modulus and G'' to the viscous modulus. This gives an indication of the balance of contribution arising from the viscous and elastic properties of the material.

The skin adhesion properties of the bioadhesive composition having regards to the rate of change of tan delta (G''/G') against frequency in a diagnostic portion of the frequency range 0.01 to 300 rad/s at 37°C can corresponds to many bioadhesive compositions not covered by the examples and the polymers mentioned in the description.

The claims cover all products/methods having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such products/methods. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the product/method by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the products/methods prepared in the examples 1 to 13 and closely related homologous compounds mentioned in the description at pages 15 to 17.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/GB 00/00304

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0855190 A	29-07-1998	EP 0850619 A	01-07-1998
		EP 0853934 A	22-07-1998
		AU 5385398 A	17-07-1998
		AU 5531598 A	17-07-1998
		AU 5612598 A	17-07-1998
		AU 5612698 A	17-07-1998
		AU 5612998 A	17-07-1998
		AU 5619598 A	17-07-1998
		AU 5619698 A	17-07-1998
		AU 5619798 A	17-07-1998
		AU 5708898 A	17-07-1998
		AU 5709198 A	17-07-1998
		AU 5709498 A	17-07-1998
		AU 5801498 A	17-07-1998
		AU 5801598 A	17-07-1998
		EP 0850624 A	01-07-1998
		EP 0850628 A	01-07-1998
		EP 0852149 A	08-07-1998
		EP 0850649 A	01-07-1998
		EP 0948364 A	13-10-1999
		EP 0957871 A	24-11-1999
		EP 0948365 A	13-10-1999
		EP 0968007 A	05-01-2000
		EP 0946213 A	06-10-1999
		EP 0946214 A	06-10-1999
		EP 0946215 A	06-10-1999
		EP 0948366 A	13-10-1999
		EP 0948367 A	13-10-1999
		EP 0948368 A	13-10-1999
		EP 0948369 A	13-10-1999
		NO 993054 A	23-08-1999
		NO 993060 A	23-08-1999
		WO 9827909 A	02-07-1998
		WO 9828014 A	02-07-1998
		WO 9828015 A	02-07-1998
		WO 9827914 A	02-07-1998
		WO 9828016 A	02-07-1998
		WO 9828018 A	02-07-1998
		WO 9828019 A	02-07-1998
		WO 9828020 A	02-07-1998
		WO 9828021 A	02-07-1998
		WO 9827918 A	02-07-1998
		WO 9828022 A	02-07-1998
		WO 9828023 A	02-07-1998
		WO 9828024 A	02-07-1998
		ZA 9711595 A	22-09-1998
US 5173302 A	22-12-1992	CA 2067798 A	29-03-1992
		EP 0503009 A	16-09-1992
		JP 5502239 T	22-04-1993
		WO 9205810 A	16-04-1992
EP 0676457 A	11-10-1995	CA 2146286 A	07-10-1995
		DE 69505176 D	12-11-1998
		DE 69505176 T	10-06-1999
		US 5614586 A	25-03-1997
		US 5674275 A	07-10-1997

INTERNATIONAL SEARCH REPORT

information on patent family members

Inter. Application No

PCT/GB 00/00304

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5670557 A	23-09-1997	AU 6283796 A	26-02-1997
		CN 1191546 A	26-08-1998
		EP 0840753 A	13-05-1998
		JP 11510530 T	14-09-1999
		WO 9705171 A	13-02-1997
		US 5779632 A	14-07-1998
		US 5853750 A	29-12-1998
		US 5952398 A	14-09-1999
		AU 1599595 A	15-08-1995
		CA 2179907 A	03-08-1995
		CN 1139946 A	08-01-1997
		DE 69509365 D	02-06-1999
		DE 69509365 T	16-12-1999
		EP 0741765 A	13-11-1996
		JP 9509196 T	16-09-1997
		WO 9520634 A	03-08-1995
		US 5674561 A	07-10-1997
EP 0012402 A	25-06-1980	CA 1153427 A	06-09-1983
		CA 1237229 C	24-05-1988
		DE 2966933 D	24-05-1984
		ES 486582 A	16-06-1980
		FR 2443843 A	11-07-1980
		JP 1436057 C	25-04-1988
		JP 55081635 A	19-06-1980
		JP 62044933 B	24-09-1987
		US 4391278 A	05-07-1983
WO 0006214 A	10-02-2000	WO 0007636 A	17-02-2000
		WO 0006215 A	10-02-2000
		WO 0007637 A	17-02-2000
		WO 0007638 A	17-02-2000